Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London

Drug Profile

Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London

Alternative Names: Autologous EBV-CTL - bluebird; Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London; EBV-CTL - bluebird/University College London; EBV-specific T-cells - bluebird bio/University College London; Epstein-Barr virus specific cytotoxic T-lymphocytes - bluebird bio/University College London; Tacrolimus resistant EBV-CTL -bluebird; Tacrolimus-resistant autologous Epstein-Barr virus-specific T-cell therapy - bluebird

Latest Information Update: 04 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator bluebird bio; University College London
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Post-transplant lymphoproliferative disorder

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Post-transplant lymphoproliferative disorder in United Kingdom prior to April 2017 (IV)
  • 24 Apr 2017 bluebird bio in collaboration with University College London plans a phase I trial for Post-transplant lymphoproliferative disorder (In infants; In children; In adolescents; In adults; In the elderly) in United Kingdom (NCT03131934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top